GFAP and head injury: In 2018, the Food and Drug Administration (FDA) permitted the marketing of a panel of two biomarkers, glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1), as a screening test for intracranial abnormalities in adults with head injuries presenting to the ED setting (20, 21).